Delivery Order SPE2DB20D1110-SPE2DB25FK31T
- Not listed
- The Defense Logistics Agency awarded a $40,681.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $33,157.91. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 6, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic immunosuppressant medication used to treat various allergic and...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors, valued at $15,032.79 under a firm fixed-price contract. The order was awarded competitively without set-aside provisions on August 1, 2025, with an ultimate completion date of August 4, 2025. Performance of this delivery will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK31TDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors, with a contract ceiling value of $10,915.00. This is a firm fixed price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, and serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company demonstrates significant capacity to fulfill federal pharmaceutical supply requirements through its extensive portfolio of delivery orders with DLA, covering medications across multiple therapeutic domains. Dupixent (dupilumab) is a prescription biologic medication primarily used for treating atopic dermatitis, asthma, and chronic rhinosinusitis, making this delivery order consistent with the Defense Health Agency's medical supply needs for military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 8/5/25 |